eSScape

Efgartigimod PH20 SC in adult participants with systemic sclerosis. A phase 2, randomised, double-blind, placebo-controlled trial

Condition studied : Systemic sclerosis
Treatment : Injection of Efgartigimod or placebo
Inclusion criteria :

– Moderate to severe skin involvement
– Negative anti-RNA polymerase-3 autoantibodies + first non-Raynaud’s symptom < 5 years OR positive anti-RNA polymerase-3 autoantibodies + first non-Raynaud’s symptom < 2 years

Exclusion criteria :

– Severe digital vasculopathy within the last 3 months
– Pulmonary arterial hypertension
– Severe pulmonary involvement

Sponsor : ARGX
Principal Investigator : Pr. Christian Jorgensen
: NCT06655155 | A Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Systemic Sclerosis | ClinicalTrials.gov
Investigator
Pr. Christian Jorgensen
Director
Rechercher sur le site